Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AAA614

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

3B Pharma, Clovis, Novartis

Drug class:

Ionizing radiation emitter, FAP inhibitor

Related drugs:

‹

[177Lu]FAPI-46 (0)

177Lu-satetraxetan-lilotomab (4)

lutetium Lu 177 vipivotide tetraxetan (4)

ibritumomab tiuxetan (3)

Actinium-225 conjugated to daratumumab (2)

lutetium Lu 177 dotatate (2)

radium Ra-223 dichloride (2)

177Lu-DTPA-omburtamab (0)

177Lu-LNC1003 (0)

177Lu-LNC1004 (0)

177Lu-LNC1010 (0)

177Lu-P17-087 (0)

177Lu-P17-088 (0)

177Lu-PSMA-R2 (0)

iodine I 131 tositumomab (0)

samarium-153 DOTMP (0)

epratuzumab Y-90 (0)

lutetium-177 DOTA satoreotide (0)

67Cu MeCOSar octreotate (0)

177Lu-edotreotide (0)

177Lu-DOTA-EB-FAPI (0)

[177Lu]FAPI-46 (0)

›

FAP expression	Sarcoma	FAP expression	Sarcoma	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D
FAP expression	Pancreatic Cancer	FAP expression	Pancreatic Cancer	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D	AAA614 Sensitive: D – Preclinical AAA614 Sensitive : D